SIGA Technologies Employee Directory
Biotechnology ResearchNew York, United States51-200 Employees
SIGA Technologies is a biotechnology company devoted to developing medicines aimed at preventing and treating emerging infectious diseases that have high unmet medical needs. Its focus includes infections caused by orthopoxviruses, such as smallpox and mpox, with products intended to help patients worldwide. Based in New York City, New York, SIGA operates within the biotechnology research sector and maintains a mid-sized workforce. A notable recent development is a 2024 exclusive license agreement with Vanderbilt University for novel poxvirus monoclonal antibodies.